Braden Leonard’s BML Investment Partners disclosed a 15.2% stake in Metracrine (MTCR), which represents over 6.4M shares. The filing with the SEC allows for activism. BML said it plans to vote against the company’s proposed merger with Equillium (EQ) "unless the collar is adjusted to reflect the current Equillium share price."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MTCR:
